Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells by unknown
ter Braak et al. Breast Cancer Research  (2015) 17:97 
DOI 10.1186/s13058-015-0600-5RESEARCH ARTICLE Open AccessAlternative signaling network activation through
different insulin receptor family members
caused by pro-mitogenic antidiabetic insulin
analogues in human mammary epithelial cells
Bas ter Braak1, Steven Wink1, Esmee Koedoot1, Chantal Pont1, Christine Siezen2, Jan Willem van der Laan1,2,3*
and Bob van de Water1*Abstract
Introduction: Insulin analogues are designed to have improved pharmacokinetic parameters compared to regular
human insulin. This provides a sustained control of blood glucose levels in diabetic patients. All novel insulin analogues
are tested for their mitogenic side effects, however these assays do not take into account the molecular mode of
action of different insulin analogues. Insulin analogues can bind the insulin receptor and the insulin-like growth factor 1
receptor with different affinities and consequently will activate different downstream signaling pathways.
Methods: Here we used a panel of MCF7 human breast cancer cell lines that selectively express either one of the
isoforms of the INSR or the IGF1R. We applied a transcriptomics approach to assess the differential transcriptional
programs activated in these cells by either insulin, IGF1 or X10 treatment.
Results: Based on the differentially expressed genes between insulin versus IGF1 and X10 treatment, we retrieved a
mitogenic classifier gene set. Validation by RT-qPCR confirmed the robustness of this gene set. The translational
potential of these mitogenic classifier genes was examined in primary human mammary cells and in mammary
gland tissue of mice in an in vivo model. The predictive power of the classifier genes was evaluated by testing
all commercial insulin analogues in the in vitro model and defined X10 and glargine as the most potent mitogenic
insulin analogues.
Conclusions: We propose that these mitogenic classifier genes can be used to test the mitogenic potential of novel
insulin analogues as well as other alternative molecules with an anticipated affinity for the IGF1R.Introduction
Diabetes mellitus is the most common endocrine disease
with over 380 million patients in 2013, worldwide [1]. A
common treatment for both type-1 and type-2 diabetics is
the use of insulin analogues, which are insulin-like mole-
cules with altered pharmacokinetic parameters so that they
are either absorbed more rapidly or slower compared to
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vides the patient with normal blood glucose levels. These
insulin analogues have been used for several decades, but
recently some epidemiological studies found a correlation
between the use of some of these compounds and cancer
occurrence, especially breast cancer [2–5]. On the con-
trary, other epidemiological studies could not confirm
these results and suggested that confounding factors (e.g.
hyperinsulinemia and age of patients) might have caused
this effect [6–11]. There are two main hypotheses by
which insulin analogues might increase the risk of cancer
[12]. First, the changes to the molecular structure of insu-
lin affect the binding properties toward different receptors
(e.g. the A isoform of insulin receptor (IRA) [13] orarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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consequence these insulin analogues have an increased
mitogenic potential. In this scenario the insulin ana-
logues could act either as a tumor initiator by trans-
forming benign or (pre)neoplastic cells, which often
express increased levels of IRA and IGF1R [15], or as
a tumor promoter by stimulating the increased growth
potential of these cells. Second, insulin analogues
might induce mutagenic action either directly or indir-
ectly as a statistical consequence of the increased
mitogenic potential. However, evidence for an indirect
enhanced mutagenic effect due to insulin analogue
treatment has never been observed and, therefore, the
first hypothesis is the most plausible scenario. As indi-
cated before, some insulin analogues have an increased
binding potential toward the IGF1R [16] and/or a pro-
longed occupancy time for the IRA [17]. A simple
evaluation of this effect has been the proliferative po-
tential of insulin analogues, but the obtained results
strongly depend on the used cell model and experi-
mental procedures (reviewed in Bronsveld et al.)
(Bronsveld, 2015 manuscript submitted) and are ex-
cluding the systematic evaluation of the actual role of
the different insulin receptor families. We have devel-
oped a panel of MCF7 cell lines that express select-
ively either the IRA, the B isoform of insulin receptor
(IRB) or IGF1R [18], which now allows us to differen-
tiate the effect of individual insulin analogues on cellu-
lar signaling more precisely.
The downstream signaling of IRA and IGF1R is a
complex diverse network leading to the activation of a
diverse set of downstream cell signaling cascades and
various transcription factors. The difference in activating
either insulin receptor (INSR) or IGF1R signaling ultim-
ately defines the cell biological outcome, roughly meta-
bolic control versus promitogenic signaling respectively.
The diversity of signaling events can be mapped using
proteome-wide phosphoproteomics analysis [18]. Alter-
natively genome-wide transcriptomics may more broadly
define the different signaling networks that are activated
by either INSR or IGF1R. For the safety evaluation of
novel chemical entities, transcriptomics-based profiling
is often used to correctly classify the potential toxic
properties [19, 20]. Given the differential activation of
INSR and IGF1R by some insulin analogues, we antici-
pate that an IGF1R activation gene expression signature
would be advantageous to define the mode of action of
highly mitogenic insulin analogues. Therefore, in this
study we used our MCF7 human breast cancer cell lines
that differentially express the different insulin receptor
family members [18]. We used transcriptomics to define
gene sets involved in insulin analogue-induced mito-
genic signaling. These genes are candidate mitogenic
classifiers to predict the mitogenic potential of newlydeveloped insulin analogues or growth factors in general
that act on the IGF1R.
Methods
Primary cell isolation, cell line generation and cell
culturing
Cell lines based on the human breast cancer MCF7 cell
lines, which predominantly express the IRA, IRB or
IGF1R have been described previously [18]. All MCF7
derivatives were cultured in RPMI 1640 medium (Gibco,
Invitrogen, Carlsbad, CA, USA) supplemented with 10 %
fetal bovine serum (FBS) and 100 U/mL penicillin-
streptomycin (Invitrogen).
Primary human mammary cells have been isolated
from cryopreserved biopsies of two individuals as de-
scribed previously [21]. The two biopsies were obtained
from two female patients who had undergone breast
cancer-related surgery at the Leiden University Medical
Center (LUMC). Procedures were followed according to
the Dutch Medical Treatment Act and the study proto-
col was compliant with “the Code of proper secondary
use of human tissue in the Netherlands” issued by the
Dutch Federation of Medical Scientific Societies and ap-
proved by the Medical Ethics committee of the LUMC
(P10.226). Specimens were coded anonymously in a way
that they were not traceable back to the patient by la-
boratory workers. As much as possible fat tissue was re-
moved from the human mammary biopsies, thereafter
they were cut into 8-mm3 pieces, which were then dried
and attached to the culture flask for 30 min. Twenty
percent of FBS containing Dulbecco’s modified Eagle’s
medium (DMEM)-F12 medium (Gibco/Invitrogen, Breda,
the Netherlands) was gently added and refreshed every
5 days. Around the edges of the tissue, cells (mainly fibro-
blasts) started growing and after 3 weeks the culture flask
was confluent with cells. The fraction of epithelial cells
was enriched by multiple short trypsinization steps in
which part of the fibroblasts were removed. For two more
passages the cells were cultured in HuMEC Ready
Medium (Gibco/Invitrogen). After this step the primary
mammary cells were cultured in DMEM-F12 medium
supplemented with 10 % FBS and 100 U/mL penicillin-
streptomycin (Invitrogen).
Insulin, insulin analogues and IGF1 in vitro stimulation
Prior to compound stimulation the cells were starved
in 5 % charcoal/dextran-stripped fetal bovine serum
(CDFBS, GE Healthcare HyClone, Utah, USA)-containing
medium. Stimulations included: insulin neutral protamine
Hagedorn (NPH) (Insuman Basal, Sanofi Aventis, Paris,
France), insulin glargine (Lantus, Sanofi Aventis), first me-
tabolite of glargine (M1, Sanofi Aventis), second metabolite
of glargine (M2, Sanofi Aventis), glulisine (Apidra, Sanofi
Aventis), lispro (Humalog, Eli Lilly, Indianapolis, IN, USA),
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 3 of 15insulin X10 (not marketed, Novo Nordisk, Bagsvaerd,
Denmark), aspart (B28Asp, Novo Nordisk), detemir (Leve-
mir, Novo Nordisk) and insulin-like growth factor 1 (IGF1)
(Increlex, Ipsen, Basking Ridge, NJ, USA). All insulin ana-
logues were dissolved in their original vehicle solutions
[18]. For the in vitro experiments 1000× stock concentra-
tions were prepared. Except for the first exposure experi-
ment (Fig. 1c) in which a dose response of 10, 33 and 100
nM was used, all exposures were performed with a concen-
tration of 10 nM.
siRNA transfection
A transient transfection method with Smartpool siRNA
mix (Dharmacon Technologies, Thermo Fisher Scientific,
Lafayette, CO, USA) was used to test the effect of in-
dividual gene on cell proliferation. For this, 10,000
MCF7 cells per well were seeded in 96-well plates in
complete growth medium. Twenty-four hours after
seeding, 50 nM Smartpool siRNA mix was delivered
to the cells using a standard transfection method with
DharmaFECT 4 transfection reagent (Dharmacon
Technologies) according to the company’s instructions.
Twenty-four hours after transfection, the small interfer-
ing RNA (siRNA) transfection mixture was replaced with
5 % CDFBS starvation medium for drug treatment and
sulphorhodamine B (SRB) proliferation assay.
Sulforhodamine B colorimetric assay determining
cell proliferation
A SRB assay was used to measure the total amount of
protein as a measure for cell proliferation. Transfected
and drug-treated cells in 96-well plates were fixed with
30 μl 50 % trichloroacetic acid directly added to 100 μl
of assay medium per well for 1 h at 4 °C on a shaker,
washed five times with distilled water and air-dried.
Fixed cells were stained with 60 μl of 0.4 % SRB
(dissolved in 1 % acetic acid) at room temperature on a
shaker for 30 min. After the SRB protein binding, the
plates were washed five times with 1 % acetic acid to re-
move unbound dye and air-dried between the washing
steps. Next, the protein-bound SRB in each well was
solubilized in 200 μl 10 mM unbuffered Tris solution
(pH >10) for 10 min on a plate shaker. Absorbance was
measured at 530 nm with a FLUOstar OPTIMA plate
reader (BMG Labtech, Offenburg, Germany).
Western blotting
Western blotting was used to determine the knockdown
efficiency of the siRNA transfection. To prepare cell ly-
sates for Western blot analysis, cells were washed two
times with ice-cold phosphate-buffered saline (PBS) and
lysed with 1 × SPB with 1:20 β-mercaptoethanol. Sam-
ples were boiled at 95 °C for 5 min and stored at −20 °C.
Before loading, samples were denatured at 95 °Cfor 5 min. A total of 20 μl (about 30 ug) protein solution
per lane was separated by SDS-polyacrlyamide gel
electrophoresis on a 7.5 % acrylamide gel and electrophor-
etically transferred to a polyvinylidene fluoride membrane
(Merck Millipore, Billerica, MA, USA). Prior to primary
antibody probe, membranes were blocked for 1 h at room
temperature with 5 % bovine serum albumin (BSA) or 5 %
milk in Tris-buffered saline and Tween 20 (TBST) buffer
(100 mM Tris, pH 7.4, 500 mM NaCl, 0.05 % Tween 20).
ERK, AKT, PTEN and tubulin antibodies were probed
in 1 % BSA-TBST buffer, whereas IGF1Rβ antibodies
were probed in 1 % milk-TBST buffer. Horseradish
peroxidase (HRP)-conjugated secondary antibody incu-
bation was performed in 1 % BSA-TBST or 1 % milk-
TBST buffer, corresponding to the primary antibodies
used. Protein bands were visualized by using the ECL
(Amersham) method, after which the membrane was
scanned by using a Typhoon 9400 imager (GE Healthcare,
Amersham, UK). Anti-phospho-Akt (Ser473) and anti-
phospho-Erk (Thr202, Tyr204) have been purchased from
Cell Signaling Technology, Danvers, MA, USA). For a
detailed description of the methods and origin of the
antibodies we refer to our prior publications [18, 22].
Microarray studies
For the microarray, the cells were seeded at a confluence
of 60 % in 6-cm plates, starved for 2 days in 5 % CDFBS-
containing medium, followed by 1 h or 6 h compound
stimulation (10 nM) in serum-free medium. Small and
large RNA was isolated and purified using NucleoSpin®
miRNA isolation kit (Macherey-Nagel, Düren, Germany)
according to the manufacturer’s instructions. RNA
quality and integrity were assessed by using the Agilent
2100 Bioanalyzer System (Agilent Technologies, Santa
Clara, CA, USA). The Affymetrix 3′ IVT Express Kit
(Affymetrix, Santa Clara, CA, USA) was used to
synthesize biotin-labeled cRNA, and this was hybrid-
ized to an Affymetrix HG-U133 Plus PM Array plate
reader. Probe annotation was performed using the
hgu133plus2.db package and probe mapping was per-
formed with the hgu133plus2cdf package installed using
Bioconductor version 3.0. Probe-wise background correc-
tion (Robust Multi-array Average expression measure),
between-array normalization (quantile normalization) and
probe set summaries (median polish algorithm) were
calculated with the RMA function of the Affymetrix
package (Affy package version 1.38.1) [23]. The normal-
ized data were statistically analyzed for differential gene
expression using a linear model with coefficients for
each experimental group [24]. A contrast analysis was
applied to compare each exposure with the correspond-
ing vehicle control. For hypothesis testing the moder-
ated t-statistic by empirical Bayes moderation was used
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Fig. 1 Knockdown of signaling components critical in the INSR and IGF1R pathway reveals common canonical core in IRA-, IRB- and IGF1R-induced
proliferation signaling. a The canonical INSR and IGF1R signaling pathway with the focus on proliferative and apoptotic biological outcomes. b Western
blot analysis of the cell line panel, based on the human breast cancer cell line MCF7 with stable retroviral overexpression (IRA, IRB and IGF1R)
in combination with a stable short hairpin knockdown (INSR and IGF1R). Cells have been treated with 0, 10, 33 or 100 nM of insulin X10 for
30 min. Downstream signaling pathway activation of the receptors is intact as is indicated by the dose-dependent activation of p-ERK/p-AKT.
c Western blot analysis of siRNA transfection efficiency in the MCF7 IGF1R cell line, 1 day and 5 days posttransfection and the effect of the
knockdown on proliferation measured with the SRB proliferation assay. d The effect of transient knockdown of ten important signaling molecules
(INSR, IGF1R, GRB2, RAF1, ERK2, IRS1, PIK3CA, PTEN, AKT2 and GSK3B) in the INSR and IGF1R signaling pathways on SRB proliferation measured in
the different MCF7 derivatives (MCF7 IRA, MCF7 IRB and MCF7 IGF1R). e The effect of treatment and knockdown of key signaling molecules in INSR
and IGF1R signaling on SRB proliferation measured in MCF7 IGF1R. (*p <0.05, **p <0.01, ***p <0.001). IGF1R insulin-like growth factor 1 receptor, INSR
insulin receptor, IRA A isoform of INSR, IRB B isoform of INSR; siRNA small interfering RNA, SRB sulphorhodamine B
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LIMMA package [26]. The microarray data is publically
available at the Gene Expression Omnibus (GEO) data-
base via accession number GSE65398.
RT-qPCR
For the qPCR analysis, messenger RNA from MCF7 cells
(80 % confluent 6-well) or mammary glands (30 μg tissue)
was isolated/purified using NucleoSpin® miRNA isolation
kit (Macherey-Nagel). cDNA was made using the universal
cDNA synthesis kit (Exiqon, Vedbaek, Denmark). qPCR
was performed in triplicate using SYBR Green PCR
(Applied Biosystems, Carlsbad, CA, USA) on a 7900HT
Fast Real-Time PCR system (Applied Biosystems). Primers
targeting the mitogenic classifiers have been manually de-
signed and are listed in the additional material (Table S1 in
Additional file 1). qPCR data were collected and analyzed
using SDS2.3 software (Applied Biosystems). Relative gene
expression was calculated after correction for β-actin ex-
pression using the 2-ΔΔQ method. Data are presented as
fold change (or log2 fold change) compared to vehicle
stimulation.
Animal experiments
Forty female 12-week-old inbred FVB/NRj mice were
obtained from Janvier Labs, Orleans, France. Housing
and experiments were performed according to the Dutch
guidelines for the care and use of laboratory animals
(UL-DEC-14020). RM2 food SDS (Technilab-BMI,
Someren, Holland) and water were provided ad libitum.
Animals received a single subcutaneous injection of 100 μl
compound/vehicle solution. The doses were chosen so that
the glucose drop was constant among the different com-
pounds (see Figure S3A in Additional file 2) (glargine
and insulin 100 nmol/kg, X10 1200 nmol/kg and IGF1
12.5 mg/kg). One or six hours after the injection the mice
were sacrificed, blood was collected (mini collect, Greiner/
Omnilabo, Breda, Holland), blood glucose levels were mea-
sured (Freestyle light, 70812–70, Abbott Laboratories,
Abbott Park, IL, USA), the third and fourth mammary
glands were isolated and used for Western blot protein
quantification and quantitative PCR respectively [18, 22].For each condition (treatment/time point) four mice were
included.
Statistical analysis
For the statistical analysis of the microarray data, R
(version 3.1) software was used. The rest of the ana-
lysis was performed with Graphpad Prism version 4.00
(Graphpad Software, San Diego, CA, USA). Student’s t
tests were used to determine significance between condi-
tions. P values lower than 0.05 were considered to be sig-
nificant. In all graphs the error bars represent standard
deviations.
Results
Mitogenic signaling is regulated via highly similar signaling
cascades in the INSR and IGF1R signaling pathway
To better understand the involvement of the IRA, IRB
and IGF1R pathways (Fig. 1a) in the context of mito-
genic signaling of insulin analogues, we used our previ-
ously described human MCF7 breast cancer cell lines
that express either IRA, IRB or IGF1R [18]. Exposure
of these individual cells to the promitogenic insulin
analogue X10 that activates both the INSR and the
IGF1R, resulted in intact downstream signaling cascades
in all three cell lines, indicating functionality of the re-
ceptors (Fig. 1b). As a next step, we wanted to ensure
that the IRA, IRB and IGF1R are not entirely different
regarding their key intracellular proliferative signaling
pathways. For this purpose, we tested the proliferative
potential of the cells after knockdown of several key sig-
naling molecules in these pathways (Fig. 1a). As a first
step, we optimized the knockdown efficiency using
IGF1R and ERK1/2 as controls. The knockdown effi-
ciency of IGF1R was almost 100 % and constant over
5 days of culturing; the knockdown efficiency of ERK1
and ERK2 was around 50 % after day 1 up to 95 % at
day 5 (Fig. 1c), we assume that the knockdown efficiency
is constant for other targets but obviously it was practic-
ally not feasible to test them all in this study. To assess
the proliferative and antiapoptotic effects of these
knockdowns, we used the SRB proliferation assay. After
knockdown of ERK1/2 and IGF1R, the amount of cells
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25 % (Fig. 1c), indicating that the SRB proliferation assay
is a sensitive assay to pick up any antiproliferative
effects.
Next, we determined the effect on proliferation of ten
individual signaling molecules that are key in the INSR/
IGF1R signaling pathway (INSR, IGF1R, GRB2, RAF1,
ERK2, IRS1, PI3KCA, PTEN, AKT2, GSK3B) in un-
treated IRA, IRB and IGF1R MCF7 cell lines (Fig. 1d).
As expected, the INSR knockdown only significantly
affected the proliferative behavior in the IRA and IRB
cell line. Similarly, the siIGF1R only significantly reduced
the proliferative behavior in the MCF7 IGF1R cell line.
Transient knockdown of downstream targets in the
MAPK signaling cascade (GRB2, RAF1 and ERK2) all
had a significant inhibiting effect on proliferation. Also
knockdown of targets in the PI3K signaling cascade
(IRS1, PI3KCA and AKT2) had a significantly reduced
proliferative effect in all cell lines. It has to be noted that
different members of the AKT family have redundant
functions and can therefore take over the loss of func-
tion of the silenced member. We expect that a knock-
down of all three members of AKT would lead to an
even stronger effect on cell proliferation [27]. As antici-
pated, a knockdown of PTEN increased the proliferative
potential in these cells, since PTEN acts as a tumor sup-
pressor through dephosphorylation of phosphoinositide-
3 phosphate, thereby negatively regulating PI3K signal-
ing. Also GSK3B knockdown showed an increase in pro-
liferation. The antiapoptotic effects of GSK3B are likely
to cause this effect, which was only detected in the
IGF1R-overexpressing cell line. Finally, the proliferative
potential of nonstimulated MCF7 IGF1R cells treated
with different siRNAs was compared to insulin and
IGF1 treatment conditions (Fig. 1e). The effect of the
stimulation itself was clearly detectable as the SRB ab-
sorbance increased from 1.04 (untreated, upper graph)
to 1.81 (insulin treated, middle graph) to 2.61 (IGF1
treated, lower graph) in the mock condition. Further-
more the effects of the different siRNA knockdowns on
proliferation became more prominent in the stimulation
conditions. Interestingly, in the insulin-stimulated condi-
tion the siINSR significantly affected proliferation in the
IGF1R cell line, suggesting that the low levels of INSR in
this cell line (Fig. 1b) are involved in proliferation once
stimulated with high levels (10 nM) of insulin.
It could be argued that the effects described above are
not (solely) due to promitogenic effects, since the INSR/
IGF1R signaling pathway can also induce antiapoptotic
effects (see Fig. 1a). These antiapoptotic effects could
also lead to more cells and thus a higher SRB assay read-
out. To investigate this, we determined the apoptotic
fraction with a FACS analysis upon stimulation with the
different growth factors (insulin, glargine, X10, IGF1) at0, 10 and 100 nM. As expected, we found a slightly, but
dose-dependent, higher fraction of apoptotic cells in the
growth factor-stimulated cells (approximately 6 %) ver-
sus the unstimulated (approximately 4 %) (data not
shown). Since this is such a small difference, we assume
that the antiapoptotic effects play a minor role com-
pared to the promitogenic effects in the growth factor
stimulation experiments.
In conclusion, these combined data indicates that the
core signaling pathways involved in cell proliferation are
similar in the entire MCF7 INSR family cell panel, allow-
ing us to use this panel to further unravel the signaling
events that can differentiate between INSR versus IGF1R
acting insulin analogues.
Insulin analogues trigger different transcriptomes in the
different cell lines
To detect the differences in gene expression levels be-
tween the different cell lines, we next performed a
microarray experiment using the same cell line panel
(Fig. 1b). We included five different stimulation conditions
(vehicle, insulin, glargine, X10 and IGF1 stimulation). This
allowed the comparison of the transcriptomes of the dif-
ferent treatments. We also included two different time
points, thus enabling observation of possible time dynam-
ics. Using a principal component analysis (PCA) a clear
separation of the different treatments and cell lines condi-
tions was observed (Fig. 2a). The PCA indicated that the
transcriptome after IGF1 treatment was most different
from vehicle stimulation. Glargine and X10 treatments
cluster together and insulin treatment is closest to the
vehicle-treated situation. Triplicate (or quadruplicate for
the vehicle) samples from independent biological experi-
ments were close to each other, indicating a strong robust-
ness of the assay.
We determined the significantly differentially expressed
genes (DEGs) per condition (1 h stimulation, Fig. 2b; 6 h
stimulation, Fig. 2c). Most DEGs were observed in the
IGF1R cell line, which is consistent with the strongest sep-
aration of this cell line in the PCA analysis (Fig. 2a). We
combined all DEGs per cell line and determined the over-
lap from the different treatments. There was a 43 % over-
lap in the DEGs between the different cell lines. We also
compared the treatment-specific responses independent of
the cell line (right Venn diagram Fig. 2b/c). Again, IGF1
treatment has the biggest impact on the transcriptome,
and the highest overlap with the X10 and glargine treat-
ment. The total number of DEGs 6 h after stimulation
(Fig. 2c) is considerably larger compared to the 1 h stimu-
lation (Fig. 2b). After 6 h of stimulation there was a large
overlap of DEGs among the different cell lines as well as
treatments (3531), suggesting that at this time point more
general mechanisms were activated that are similar for the
different treatment conditions. Venn diagrams of all the
AB
C
Fig. 2 Experimental setup of microarray experiment. a Two-dimensional principal component analysis plot of the microarray gene expression
data. A clear separation of the different treatments (indicated by the different colors of the dots), cell lines (different shapes) and time points
(light; 1 h vs. dark; 6 h) could be observed. The triplicates or quadruplicates are as expected very close to each other. b Number of significantly
differentially expressed genes between the different cell lines at T = 1 h. The first Venn diagram shows overlap of the significant differentially
expressed genes (DEGs) per cell line at T = 1 h. The second Venn diagram shows overlap of the significant DEGs per treatment at T = 1. c As in
(b) but then for T = 6 h
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ial (Figure S1 in Additional file 3). A noteworthy finding is
the very high number of DEGs in the X10 stimulation via
the IRA at T = 1 h.
Differential pathway activation by the various insulin
analogues
To further understand the biological pathways upregu-
lated by these different compounds we performed an
Ingenuity Pathway Analysis (IPA), focusing on the
MCF7 IGF1R cell line using both time points (Venn dia-
gram Fig. 3a). A mitogenic cluster was defined that
included all DEGs of IGF1 treatment only, or IGF treat-
ment in combination with X10 and/or glargine treat-
ment. We included glargine treatment in this cluster as
glargine, like X10, is highly mitogenic in the absence of
serum [18]. In a similar way a metabolic cluster was
defined, including all DEGs of insulin treatment only,
or insulin treatment in combination with glargine
and/or X10 since all these compounds are known to
have a strong metabolic effect in vivo. Using IPA we
found ‘ERK/MAPK’ and ‘p70S6K’ signaling pathways
significantly enriched in the mitogenic cluster, while
the ‘PI3K’ and ‘cell cycle control’ pathways were not
enriched. For the metabolic cluster the IPA results
were the other way around. We also performed IPA
analysis on the individual treatment DEG lists. ‘Cell
cycle control of chromosomal replication’ was highly
enriched after treatment with compounds with a high
affinity for the INSR (insulin, glargine and X10).
Other metabolic processes like glycogen degradation
and D-myo-inositol-5-phosphate metabolism were alsoA
Fig. 3 Pathway enrichment analysis of differentially expressed gene lists. a
MCF7 IGF1R. The mitogenic gene cluster consists of all DEGs in IGF1 treatm
treatment. Similarly, a metabolic gene cluster was defined including the ins
An Ingenuity Pathway Analysis (IPA) was performed that revealed an enrichm
cluster whereas the PI3K and cell cycle control signaling pathways were enric
DEGs of individual treatments including all cell lines and the different time po
stimulation with metabolic compounds (insulin, glargine and X10). IGF1 stimu
and p53 signaling. For insulin signaling these pathways were also enriched bu
growth factor 1 receptorenriched in the DEGs of these insulin molecules. On
the other hand PI3K/AKT, IGF1, p53 and ERK/
MAPK signaling were more enriched for the insulin-
like molecules that also have a strong affinity for the
IGR1R.
A classifier gene set predictive for the promitogen action
of insulin analogues
To evaluate which genes drive the strong mitogenic re-
sponses of IGF1R signaling we performed a variance test
with selected genes showing a strong up- or downregu-
lation after strong activation of the IGF1R. For this we
selected IGF1 and X10 exposures and contrasted this
with the weak mitogenic response inducer insulin. We
excluded glargine for the selection. In total we selected
the top ten hits in both the 1 h and 6 h hit lists (Fig. 4a).
Interestingly, many of these genes are known to play a
role in mitogenic processes, including the early growth
response (EGR) genes (all four EGR genes are in the top
20 gene list). Most of these genes have not directly been
linked to the INSR or IGF1R signaling pathway so far.
Next we validated these candidate genes using RT-qPCR
with a separate independent set of samples. For 18 of
these mitogenic classifier genes the RT-qPCR validation
was successful and showed a highly similar trend for in-
sulin, X10 and IGF1 conditions (Fig. 4b). For ZIC4 and
ZMYND8 the expression was probably too low since no
amplicon was detected even after 40 cycles. Finally, we
evaluated the effect of glargine on the expression of
these classifier genes. Importantly, the overall expression
of the classifier genes after glargine treatment was more
similar to X10 than to insulin treatment.B
Separate gene clusters were defined based on the Venn diagram of
ent alone and the combinations of IGF1 with glargine and/or X10
ulin-specific DEGs with combinations of the other insulin analogues.
ent of the ERK/MAPK and p70S6K signaling pathways in the mitogenic
hed in the metabolic cluster. b An IPA analysis was performed on the
ints. As expected the metabolic signaling (A t/m D) was upregulated after
lation led to a very significant upregulation of PI3K/AKT, ERK/MAPK, IGF1
t less significantly. DEGs differentially expressed genes; IGF1R insulin-like
AB
Fig. 4 Twenty mitogenic classifier genes discriminating between insulin and X10/IGF1 signaling. a Twenty genes (ten for each time point) were
defined of which the gene expression was most significantly up- or downregulated in X10/IGF1 vs. insulin in the MCF7 IGF1R cell line (based on
a variance test), values are presented as log2 fold changes. b Validation of 18 of these mitogenic classifier genes was successful with RT-qPCR. A
comparison is given of the microarray (top panel) vs. RT-qPCR (lower panel) gene expression of the mitogenic classifiers. Expression is indicated as
fold changes relative to unstimulated MCF7 IGF1R. IGF1 insulin-like growth factor 1, IGF1R IGF1receptor
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commercially available insulin analogues
We hypothesized that the expression of the mitogenic
classifier genes could predict the mitogenic outcome
of other insulin analogues. We performed an expos-
ure experiment with MCF7 IGF1R cells including allcommercially available insulin analogues (glargine, aspart,
lispro, glulisine, determir). Since glargine showed expres-
sion of the predictive genes (Fig. 4b), and since glargine is
rapidly metabolized into two metabolites (M1 and M2) in
serum, we also included M1 and M2 in our study. A hier-
archical clustering of the expression of all the tested
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 10 of 15classifier genes after stimulation with the different insulin
analogues was performed (Fig. 5). This resulted in the
clustering of glargine with IGF1 and X10, while the glar-
gine metabolites M1 and M2 clustered with other rela-
tively nonmitogenic insulin analogues. We calculated a
‘relative mitogenic potential’, which was determined as the
sum of the absolute values of log2 fold changes of the ex-
pression of mitogenic classifiers of one compound treat-
ment. As expected the ‘relative mitogenic potential’ was
highest for IGF1 (69), followed by glargine (40) and X10
(31). The mitogenic potential of insulin (19) was very simi-
lar to that of aspart (19) and lispro (20). M1 (10), M2 (13),
glulisine (8), and determir (7) showed a lower predicted
mitogenic potential compared to regular insulin.
Validation of mitogenic classifier genes in vitro in primary
human mammary gland cells and in vivo in mouse
mammary glands
To further validate the insulin analogue mitogenic clas-
sifier genes we tested additional in vitro and in vivo
models. We first determined the robustness of the insu-
lin analogue mitogenic classifier genes in primary cul-
tured cells isolated from human mammary glands. These
cells were anticipated to be the main target for increased
mitogenic signaling of insulin analogues in diabetic pa-
tients. Primary cells were isolated from two independent
individuals and exposed to the different insulin-likeFig. 5 The relative mitogenic potential of various insulin analogues determine
IGF1, X10, glargine, insulin, aspart, lispro, M1, glulisine, M2 and detemir and th
RT-qPCR. A hierarchical clustering of the log2 fold changes (compared to veh
sum of the absolute values of log2 fold changes of the mitogenic classifiers. IGmolecules. The activation of the INSR/IGF1R path-
way was validated by Western blotting (Figure S2 in
Additional file 4) and a clear activation of the INSR/
IGF1R as well as the PI3K/AKT signaling pathway
was observed. Next, the gene expression levels of three
mitogenic classifier genes that were upregulated (EGR4
and TNFRSF11B) or downregulated (SLC1A2) in MCF7
IGF1R cells were measured (Fig. 6a). Although the fold
change expression of these three genes in these primary
human mammary cells was not as profound compared to
the MCF7 IGF1R cells, in general the same direction of
expression was observed.
In addition, we investigated these three classifier genes
in vivo in the mammary glands of mice treated with the
different insulin analogues. In this experiment 40 wild-
type FVB mice received a subcutaneous injection of
vehicle, insulin, glargine, X10 or IGF1. A very clear and
constant drop in the glucose levels was observed 1 h
after the injections of insulin, glargine, X10 and IGF1,
indicating that these compounds did induce the ex-
pected pharmacological response (see Figure S3A in
Additional file 2). The glucose levels returned to their
normal levels (5 mmol/L) 6 h after the injection. We
then investigated the activation of the INSR and IGF1R
(see Figure S3B and C in Additional file 2). One hour
after the insulin analogue injections a clear upregulation
of p-AKT was observed, while after 6 h the p-p70S6Kd by the classifier gene expression. MCF7-IGF1R cells were exposed to
e gene expression of the mitogenic classifier genes was measured with
icle stimulation) is shown. The mitogenic potential score is the absolute
F1 insulin-like growth factor 1, IGF1R IGF1receptor
AB
Fig. 6 Validation of insulin analogue mitogenic classifier genes in primary human mammary cells and in vivo mouse mammary glands. a Primary
cells isolated from two different human mammary biopsies were exposed to insulin, glargine, X10 or IGF1 and the gene expression of EGR4,
TNFRSF11B and SLC1A2 were determined by RT-qPCR. Values are presented as fold changes relative to vehicle-treated cells. b Wild-type FVB mice
(four per condition) were subcutaneously injected with the above mentioned compounds, RNA from the mammary glands was isolated and the
gene expression of EGR4, TNFRSF11B and SLC1A2 was measured by RT-qPCR and indicated as fold change relative to gene expression
of vehicle-injected mice. IGF1 insulin-like growth factor 1
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 11 of 15levels were significantly (p = 0.0022) upregulated. Also
the insulin analogue mitogenic classifier genes showed a
very clear modulation after treatment (Fig. 6b). Thus,
EGR4 was even induced up to 18 times after IGF1
treatment and X10 also showed a clear upregulation
of this candidate gene compared to no stimulation.
Similarly, after 6 h treatment IGF1 induced
TNFRSF11B and downregulated SLC1A2 levels. For
these latter gene changes none of the other insulin-
like molecules caused a significant change in gene ex-
pression. Gene expression in glargine conditions
showed a similar trend as regular insulin, suggesting
that glargine is rapidly metabolized into M1 and M2
in vivo, which are known to be compounds with a
low promitogenic signaling potential [18].
Discussion
It is well established that insulin has strong metabolic ef-
fects and in addition mild promitogenic characteristics
[14]. Small changes in the structure of insulin have im-
proved the pharmacokinetic parameters so that the use
of the insulin analogue is more convenient for diabetic
patients. Yet, these small structural changes might also
increase the binding affinity of insulin analogues towardsthe IGF1R and, consequently, increase the mitogenic po-
tency of these molecules compared to regular insulin.
Current in vitro systems that are used to determine
mitogenic potential of insulin analogues are largely
based on the proliferation capacity and do not take into
account the molecular mechanisms of receptor signaling
(Bronsveld 2015 manuscript submitted). In this study we
used a transcriptomics approach to assess the preferen-
tial activation of promitogenic signaling pathways by
insulin analogues. We identified a subset of classifier
genes that can be used to define the primary mode of ac-
tion of insulin analogues. Moreover, we demonstrated
that these classifier genes can be translated to primary
human mammary cells as well as mouse mammary
glands in vivo. These mechanism-based novel predictive
genes are likely a more reliable method to classify the
proliferative potency of insulin analogues that act prefer-
ably on the IGF1R.
For the safety profiling of insulin analogues this in-
creased mitogenic potential is critical. Currently, there is
still a debate on the mechanism of such an increased
mitogenic potential: on one hand the high binding affin-
ity toward the IGF1R, while on the other hand a pro-
longed occupancy time toward the IRA is suggested
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 12 of 15causative [17]. In our current study, we have been in the
unique situation to evaluate these mechanisms in our
MCF7 cell line panel. We found 40 % more differentially
expressed genes in the MCF7 IGF1R cell line after X10
and glargine stimulation compared to the MCF7 IRA
cell line. These results suggest that the IGF1R is the
main receptor that is mediating downstream promito-
genic signaling after insulin analogue stimulation. This is
in line with our previous study in which we tested the
proliferative potency of nine insulin-like molecules using
the same MCF7 cell line panel and found that X10 and
glargine induce proliferation more profoundly in the
MCF7 IGF1R cells than in the MCF7 IRA cells [18]. For
this reason we based the further mitogenic classifier ana-
lysis on the MCF7 IGF1R cell line.
For the mitogenic classifier hit selection, a training set
was based on microarray gene expression of three com-
pounds, in which insulin served as the reference com-
pound with a low mitogenic potency. X10 and IGF1
served as two insulin-like molecules with a strong mito-
genic potential. This resulted in a total of 20 genes either
up- or downregulated at 1 or 6 h after IGF1 and X10
treatment that most strongly differed from the insulin
effect. Many of these genes have been associated with
mitogenic signaling but so far not directly linked to
INSR/IGF1R signaling. Strikingly, various early growth
response genes were identified: EGR1 [28], EGR2 [29],
EGR3 [30], EGR4 [31] which are all well known to
promote proliferation, survival and/or invasion path-
ways. MALL, FHL2 [32], PHLDA [33], NR4A3 [34]
and CTGF [35] are known oncogenic factors and its
gene expression is negatively associated with tumor-
free survival and/or proliferation. Interestingly, genes
(POLQ and RBM6) that were downregulated after X10/
IGF1 stimulation have been linked to proapoptotic and an-
tiproliferative effects [36, 37].
Glargine is the most frequently prescribed antidiabetic
insulin analogue. There are conflicting conclusions
regarding the intrinsic mitogenic potential of insulin
glargine [38, 39]. We purposely excluded our glargine
transcriptome analysis from the training set to identify
candidate predictive classifier genes for promitogenic
signaling by insulin analogues. This allowed us to un-
ravel the potency of glargine as a promitogenic insulin
analogue. Interestingly, the mitogenic potential of glar-
gine was even higher compared to insulin X10 (Fig. 5).
This is in full agreement with the kinase activation
measurement of INSR/IGF1R pathway components in
our previous study [18]. In diabetic patients glargine is
rapidly processed by enzymes in the serum into two
metabolically active compounds, M1 and M2, in which
M1 is most prominent metabolite [40]. Therefore, we
also determined the mitogenic potential of M1 and M2
based on the gene expression profiles of the mitogenicclassifier genes and we observed that both metabo-
lites have a mitogenic score that is even lower than
insulin. This is in agreement with previous studies in
which the mitogenic potential was based on IGF1R
binding affinity, kinase activation or proliferation as-
says [16, 18].
Two other studies also performed a mitogenic assess-
ment of a panel of insulin analogues. These studies in-
cluded a proliferation assay (Kurtzhals et al. [41]) and an
IGF1R affinity evaluation [16]. We systematically com-
pared our mitogenic classifier gene score with these two
independent functional readouts (Fig. 7). There was a
striking correlation between our classifier scoring (based
on Fig. 5) and both the proliferation and IGF1R affinity.
These combined datasets demonstrate that IGF1, X10
and glargine have a higher mitogenic potential compared
to insulin, which is associated with a high affinity for
IGF1R. Aspart and lispro have a mitogenic potency simi-
lar to each other. Determir and the two metabolites of
glargine (M1 and M2) have a lower mitogenic index
compared to regular insulin, associated with a low affin-
ity for the IGF1R.
Some epidemiological studies suggest a correlation be-
tween insulin glargine use and breast cancer occurrence
in the diabetic patients [4]. Since glargine might pro-
mote proliferation of mammary epithelial cells in vivo,
we wanted to test whether expression of some of our
classifier genes could be translated from MCF7 cells to
primary human mammary cells. We could confirm a
similar gene expression trend in primary human mam-
mary cells after stimulation with insulin, glargine, X10
and IGF1 as in MCF7. Yet, the gene expression fold
changes in the primary human mammary cells were far
lower compared to the MCF7 IGF1R cells. The reason
for this can be partly due to the isolation procedure,
which did not result in a pure population of mammary
epithelial cells. Overall, the effect of glargine in the pri-
mary human mammary cells was not as profound as for
IGF1 and X10.
Previously, we demonstrated that IGF1 and X10 sig-
nificantly promote tumorigenesis in a conditional mam-
mary gland tumor mouse model [22]. Glargine did not
significantly enhance this tumorigenesis. Therefore, we
also evaluated the translation of our classifier genes to
the in vivo situation and determined the gene expression
changes in the mammary glands of mice that received a
subcutaneous injection of the insulin-like molecules in-
sulin, IGF1, X10 and glargine. We could validate the
in vitro effect of IGF1 in the in vivo situation, indicating
that a true IGF1R response can be observed in this
model. X10 showed some correlation with the effect
of IGF1. Yet, in contrast to the in vitro data, the
gene expression profiles of glargine were more simi-
lar to insulin than to X10/IGF1. This effect is very
AB
Fig. 7 Correlation between mitogenic classifier score and the enhanced proliferation or IGF1R binding. a A correlation is presented of the
mitogenic potential based on the mitogenic classifier analysis (x-axis) vs. the mitogenic potential as determined by other studies with
proliferation assays. Sommerfeld et al. [16] expressed this score as EC50 value from their proliferation curves (left y-axis). Data from Kurtzhals et al.
[41] are expressed as fold changes compared to insulin (right y-axis). b A similar correlation graph with the mitogenic potential from this study
plotted against the IGF1R binding affinity according to two other studies. Sommerfeld et al. [16] expressed this score as IC50 value from their
competition assay curves (left y-axis). Data from Kurtzhals et al. [41] are expressed as fold changes compared to the binding affinity of insulin
toward the IGF1R (right y-axis) (data adapted from Kurtzhals et al. [41] and Sommerfeld et al. [16]). IGF1R insulin-like growth factor 1 receptor
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 13 of 15likely caused by the metabolism of insulin glargine
by factors in the serum of the blood of the mice
(similar to the glargine conversion in human serum).
We therefore speculate that the observed promito-
genic signaling events of glargine in our in vitro
breast cancer cell line models are presumably not oc-
curring under in vivo conditions in the mammarygland. Yet, we cannot exclude that IGF1R-mediated
responses by glargine take place in other tissues
in vivo.
Conclusions
In the current study we propose a new robust classifier
gene set that allows the quick, robust and quantitative
ter Braak et al. Breast Cancer Research  (2015) 17:97 Page 14 of 15analysis of the promitogenic potential of newly devel-
oped insulin analogues. These classifiers can be used
within the pharmaceutical industry as well as in a regu-
latory setting to define the safety profile of insulin ana-
logues as well as other growth factors that might act on
the IGF1R.
Additional files
Additional file 1: Table S1. Sequences of used primers. All the primers
used for the RT-qPCR experiments including primers targeting human
and mouse genes.
Additional file 2: Figure S3. Mammary gland protein levels of 40 FVB
mice subcutaneously injected with insulin-like compounds. (A) The
blood glucose levels (mmol/L) have been measured 1 h and 6 h after
subcutaneous injections with different insulin-like molecules. (B) Western
blotting of the receptors and kinases in the INSR and IGF1R pathway
measured in the mammary gland tissue; samples were from 1 h (left graph)
or 6 h (right graph) after the subcutaneous injections of the presented
insulin-like molecules. (C) the quantification of activated kinases (Erk, Akt,
p70S6K, FOXO1/O3) relative to the endogous control (EC), a sample that
was loaded on every blot. N = 4.
Additional file 3: Figure S1. Venn diagrams of the differentially
expressed genes per cell line, time point and treatment showing overlap
of genes between the different conditions. (A) Venn diagram of the early
regulators (t = 1 h). The blue circle represents the hits in the IRA cell line,
yellow the IRB cell line and green the IGF1R cell line. The first graph
shows the number of hits after insulin treatment, the second graph
glargine, the third X10 and the last graph shows the number of hits after
IGF1 treatment. (B) The Venn diagrams of the late regulators (t = 6 h).
Additional file 4: Figure S2. Protein levels of primary human mammary
cells stimulated with insulin-like compounds. (A) Primary human mammary
gland cells were treated with different insulin-like molecules followed by
Western blotting for various INSR and IGF1R signaling pathway components.
(B) Quantification of Western blot data of the p-IGF1R/p-IR, p-Akt and p-Erk.
The y-axis represents the average protein expression level compared
to vehicle exposure.
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